Market Spotlight: Tumor Lysis Syndrome (TLS)
Market Spotlight: Tumor Lysis Syndrome (TLS)
$1,318.00
Tumor lysis syndrome (TLS) comprises a group of metabolic disturbances that result from either chemotherapy or spontaneously induced tumor cell death. The release of intracellular components, including nucleic acids, electrolytes, and proteins, into the systemic circulation is triggered by tumor cytotoxicity. This may result in the development of metabolic abnormalities such as hyperkalemia, hyperphosphatemia, hyperuricemia, and hypocalcemia. Clinically, this can lead to effects on multiple organs such as cardiac arrhythmias, seizures, and acute kidney injury.
Publisher: Datamonitor Healthcare
- Description
- Contents
This Market Spotlight report covers the Tumor Lysis Syndrome (TLS) market, comprising key marketed and pipeline drugs, clinical trials, probability of success, and a 10-year disease incidence forecast, as well as presenting drug-specific revenue forecasts.
Key Takeaways
- Datamonitor Healthcare estimates that in 2021, there were approximately 13,000 incident cases of tumor lysis syndrome (TLS) worldwide among individuals with high-risk malignancies (acute myeloid leukemia, acute lymphocytic leukemia, and Burkitt’s lymphoma).
- The number of incident cases is forecast to increase to 13,600 by 2026. The marketed drugs for TLS comprise the xanthine oxidase inhibitors Aloprim (allopurinol) and Uloric (febuxostat), and a recombinant urate-oxidase enzyme, Elitek (rasburicase). These therapies are administered via the intravenous and oral routes.
- There are currently no pipeline candidates in development for TLS. The overall likelihood of approval of a Phase I hematologic cancer asset is 7.7%, and the average probability a drug advances from Phase III is 56.1%. Drugs, on average, take 9.7 years from Phase I to approval, compared to 9.8 years in the overall oncology space.
- The distribution of clinical trials across Phase I–IV indicates that the majority of trials for TLS have been in the late phases of development, with 63% of trials in Phase III–IV, and 37% in Phase II.
- The US leads in terms of the number of TLS clinical trials globally. Italy and Spain lead the major European markets, while Japan has the top spot in Asia.
- Clinical trial activity in the TLS space is dominated by completed trials. Sanofi has the highest number of completed clinical trials for TLS, with 11 in total.
- Sanofi leads industry sponsors with the highest overall number of clinical trials for TLS.
CONTENTS
5 OVERVIEW
6 KEY TAKEAWAYS
7 DISEASE BACKGROUND
8 TREATMENT
8 Prophylaxis and monitoring
8 Volume expansion
8 Medical therapies
9 Renal replacement therapy
10 EPIDEMIOLOGY
10 Incidence assumptions
19 MARKETED DRUGS
21 PIPELINE DRUGS
22 PROBABILITY OF SUCCESS
23 REVENUE OPPORTUNITY
24 CLINICAL TRIAL LANDSCAPE
25 Sponsors by status
26 Sponsors by phase
27 BIBLIOGRAPHY
28 APPENDIX
LIST OF FIGURES
12 Figure 1: Trends in incident cases of TLS in selected high-risk malignancies, 2017–26
22 Figure 2: Probability of success in the hematologic cancer pipeline
24 Figure 3: Clinical trials in TLS
24 Figure 4: Top 10 drugs for clinical trials in TLS
25 Figure 5: Top 10 companies for clinical trials in TLS
25 Figure 6: Trial locations in TLS
26 Figure 7: TLS trials status
26 Figure 8: TLS trials sponsors, by phase
LIST OF TABLES
11 Table 1: Incident cases of TLS in selected high-risk malignancies, 2017–26
13 Table 2: Incidence of acute myeloid leukemia, and proportion of individuals with TLS, 2017
14 Table 3: Incident cases of TLS in acute myeloid leukemia, 2017–26
15 Table 4: Incidence of acute lymphocytic leukemia, and proportion of individuals with TLS, 2017
16 Table 5: Incident cases of TLS in acute lymphocytic leukemia, 2017–26
17 Table 6: Incidence of Burkitt’s lymphoma, and proportion of individuals with TLS, 2017
18 Table 7: Incident cases of TLS in Burkitt’s lymphoma, 2017–26
20 Table 8: Marketed drugs for TLS
23 Table 9: Historical global sales, by drug ($m), 2017–21
23 Table 10: Forecasted global sales, by drug ($m), 2022–26
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Market Spotlight: Zika virus 
Sign up to the